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Prebiotics are non-digestible food ingredients that target selected groups of the human colonic
microflora, thus having the ability to alter the composition towards a more ‘beneficial’
community, i.e. selectively increasing populations of bifidobacteria and/or lactobacilli. In the
present study the prebiotic potential of partially hydrolysed guar gum (PHGG) and fructo-
oligosaccharides (FOS) in a biscuit was assessed in human volunteers. Fluorescent in situ
hybridization using oligonucleotide probes targeting Bacteroides spp., Bifidobacterium spp.,
Clostridium spp. and Lactobacillus–Enterococcus spp. were used for the bacteriology and total
bacteria were enumerated using the fluorescent stain 40,6-diamidino-2-phenylindole. Thirty-one
volunteers consumed daily either three experimental biscuits (providing a total (g/d) of 6:6 FOS
and 3:4 PHGG) or three placebo biscuits for two 21-d crossover periods. Bifidobacteria
significantly increased in number on ingestion of the experimental biscuits compared with pre-
treatment and placebo population levels. Bifidobacterial numbers returned to pretreatment levels
within 7 d of the cessation of intake of experimental biscuits. A correlation was observed between
the initial faecal bifidobacterial numbers and the magnitude of bifidogenesis, with volunteers who
possessed low initial population levels of bifidobacteria experiencing the greatest increase in
bifidogenesis. No changes were observed in the other bacterial groups monitored during the trial.
Thus, the prebiotic nature of FOS and PHGG was maintained in a final food product as evidenced
from the selective increase in bifidobacterial numbers.
Gut microflora: Prebiotic: Gene probes
The importance of the human colon in health and disease
has become increasingly recognized with a greater under-
standing of the ecology and biological importance of the
human gastrointestinal microflora. More than 500 different
bacterial species are thought to make up the gut microbiota,
with the total number of bacterial cells present in the colon
far exceeding the total number of eukaryotic cells in the
body (Conway, 1995; Gibson & Beaumont, 1996; Tannock,
1999). Although it is known that many disease states
involve bacterial metabolism, the human gut microflora
may also be considered as very relevant to improved host
health (Gibson & Beaumont, 1996). For instance,
bifidobacteria and lactobacilli are thought to improve
resistance to gut infections by inhibiting the growth of
harmful bacteria, to reduce cholesterol levels, to improve
the immune response and to produce vitamins (Gibson,
1998; Holzapfel et al. 1998; Vanderhoof & Young, 1998;
Ziemer & Gibson, 1998). In the present study the efficacy of
biscuits containing fructo-oligosaccharides (FOS) and
partially hydrolysed guar gum (PHGG) in bringing about
a beneficial modulation of the gastrointestinal microflora
was determined. Particularly, the ability of the prebiotic
biscuits to increase numbers of bifidobacteria selectively
was assessed.
The complexity of the gut microflora presents difficulties
in monitoring this ecological phenomenon (Steer et al.
2000). Selective agars and growth conditions exist for only a
small percentage of the most numerically dominant species,
and it has been estimated that only between 10 and 50 % of
bacteria present in the human gut have been cultivated
(Langendijk et al. 1995; Wilson & Blitchington, 1996). The
phylogenetic information encoded by 16S rRNA has
enabled the development of molecular biology techniques
to allow characterization of the whole human gut microflora
(Collins & Gibson, 1999; Suau et al. 1999). Similarly,
fluorescent in situ hybridization (FISH), employing
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oligonucleotide probes targeting 16S rRNA, allows the
enumeration of both culturable and non-culturable moieties
of the gut microflora in situ in gastrointestinal and faecal
samples (Amann et al. 1995; Langendijk et al. 1995;
Zoetendal et al. 1998; Ames et al. 1999). Using FISH,
changes in population levels of specific phylogenetically
related groups of bacteria may be monitored in response to
altering ecological conditions, such as the presence of
fermentable substrate.
Manipulation of the gut microflora for improved health is
not a new concept. Probiotics, which are live microbial feed
additives thought to confer health advantages, have a long
history (Fuller & Gibson, 1997). Whilst the probiotic
approach is conceptually sound, it does have problems in
practice. Many of the health-promoting attributes of
selected probiotic strains may be determined by survival
of relatively high numbers (. 107 colony-forming units/ml
lumen contents) of metabolically active cells in the human
colon (Ducluzeau, 1989). The disparity in scientific reports
investigating the health benefits of probiotics in human
studies may at least in part be related to survivability
problems of the probiotic strain in the product, but mainly
after ingestion (MacFarlane & Gibson, 1997; Roberfroid
et al. 1998; Collins & Gibson, 1999). Prebiotics are non-
digestible food ingredients that beneficially affect the host
by selectively stimulating the growth and/or activity of one
or a limited number of bacteria in the colon that can improve
host health (Gibson & Roberfroid, 1995). Efficient
prebiotics need to induce a specific fermentation in the
colon. This process should occur by the stimulation of
benign, or potentially health-promoting, indigenous bac-
terial genera but not harmful organisms (Gibson &
Roberfroid, 1995). The premise is therefore similar to that
of dietary fibres, but with a much more tailored
fermentation, e.g. towards lactic acid-producing bacteria
(Gibson et al. 1996; Collins & Gibson, 1999).
The identification of potential prebiotics is of consider-
able scientific and commercial interest. FOS are most
commonly thought of as prebiotics and occur naturally in
onion (Allium cepa ), asparagus (Asparagus officinatis ) and
artichoke (Cynara scolymus ). They are poorly digested in
the human small intestine, but are fermented in the colon by
the resident microflora (Andersson et al. 1999). In vivo
human studies have shown that dietary addition of FOS
leads to an increase in faecal bifidobacteria (Gibson et al.
1995; Roberfroid et al. 1998; Bouhnik et al. 1999).
However, such studies were conducted using FOS as a
dietary supplement. There is no information on the prebiotic
capabilities of FOS present in a processed or final food
product consumed as part of the daily diet. Guar gum is a
soluble fibre derived from the Indian cluster bean
(Cyamopsis tetragonoloba ( psoralioides )); it forms viscous
solutions and is used worldwide in the food industry as a
thickener and emulsion stabilizer. Partially hydrolysing the
guar gum causes its viscous consistency to be lost, so that it
can be added to food in high amounts. It has been shown that
PHGG has a positive effect on diarrhoea, e.g. reducing its
duration (Alam et al. 1997) or incidence (Homann et al.
1994), as well as having an ameliorating effect in human
subjects suffering from constipation (Takahashi et al. 1994).
Similarly, Okubo et al. (1994) have demonstrated that
ingestion of PHGG at 21 g/d for 14 d resulted in a small
increase in bifidobacteria and a sizable increase in
lactobacilli in faecal samples collected from nine healthy
male volunteers. This response occurred despite the fact that
neither bifidobacteria nor lactobacilli were able to grow in
vitro using PHGG as the only C source. The addition of
fermentable fibre (21 g/d) into the colon represents a
considerable contribution to the total carbohydrate load
available to bacteria in the colon, estimated to be between
40 and 60 g/d (Hudson & Marsh, 1995). Little is known
about the prebiotic capabilities of PHGG when delivered
into the colon at lower doses.
To date, no data exist on the prebiotic effects of a final
food product containing FOS. Here we determined in a
human volunteer study the prebiotic potential of PHGG and
FOS incorporated into a biscuit. To overcome the
limitations of traditional microbiological culture in the
recovery and enumeration of specific groups of bacteria,
FISH employing 16S rRNA-targeted probes was used for
the bacteriology.
Experimental design
Experimental treatment
Experimental biscuits provided 6:6 g FOS/d and 3:4 g
PHGG/d. Active treatment was delivered as three biscuits
(37:5 g) daily, containing (w/v): wheat flour 40 %, sugar
5 %, vegetable fat 15 %, FOS 20 %, PHGG 11 %, wheat
flakes 6 %, baking powder 1 %, salt 0:2 %. Volunteers were
free to eat the biscuits at any time of day.
Placebo treatment
Placebo treatment did not contain FOS or PHGG and was
delivered as three biscuits daily, containing (w/v): wheat
flour 60 %, sugar 12 %, vegetable fat 15 %, wheat flakes
6 %, baking powder 1 %, salt 0:2 %.
Biscuits were supplied by Novartis Nutrition Research
AG, Neuenegg, Switzerland and colour coded (experimen-
tal or placebo) so as to be blind to investigator as well as
volunteers. Volunteers consumed experimental biscuits for
one 21 d period and the placebo biscuits for a second 21 d
period, i.e. the trial was conducted with a crossover between
experimental and placebo treatments. Volunteers were
randomly chosen to consume either the experimental or the
placebo biscuits during the first treatment. Sixteen
volunteers consumed the experimental biscuits during the
second treatment. Volunteers were asked to keep diaries
while ingesting biscuits, to record stool frequency and
consistency (constipation, hard, formed, soft or diarrhoea),
abdominal pain (none, mild, moderate or severe), intestinal
bloating (none, mild, moderate or severe) and flatulence
(none, mild, moderate or severe) on a daily basis. Any
concomitant medication, adverse events or volunteer
comments were also recorded.
Outline of study protocol
Subjects. Thirty-one healthy volunteers (seventeen females,
fourteen males) participated in the present study. Written
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consent was obtained from each individual and the study
was approved by the Ethics Committee of the University of
Reading. Test biscuits were administered to volunteers at
the start of each 21 d treatment period. Volunteers were
asked to eat three biscuits daily, and were free to consume
the biscuits at any time during the day. Volunteers were
asked to return any uneaten biscuits. There was a high level
of compliance (judged to be at least 90 %) with only a few
volunteers returning one or two packets of biscuits.
Pretrial assessment. Volunteers were assessed for good
health and selected on the basis of adherence to inclusion or
exclusion criteria. Two pretreatment stool samples were
taken, between day 23 and 0.
Treatment 1 (days 1–21). Volunteers consumed biscuits
(experimental or placebo) and kept diaries during treatment
1. Stool samples were obtained on two consecutive days
starting on day 19, 20, 21 or 22.
Treatment 2 (days 23–44). Volunteers consumed a
second set of biscuits (experimental or placebo) and kept
diaries during treatment 2. Stool samples were obtained on
two consecutive days starting on day 40, 41, 42 or 43.
Volunteers returned unused biscuits and completed
diaries.
Post-treatment sampling (days 49, 56 and 63). Single
post-treatment stool samples were obtained on day 47, 48,
49, 50 or 51 and on day 54, 55, 56, 57 or 58. Two stool
samples were obtained, on two consecutive days starting on
day 61, 62, 63 or 64.
Inclusion and exclusion criteria
Inclusion criteria. The criteria were: signed consent form,
age 18–50 years inclusive, BMI 20–30 kg/m2 inclusive and
good general health as determined by a medical
questionnaire.
Exclusion criteria. Volunteers were excluded from the
trial if there was evidence of physical or mental disease or
major surgery, as revealed by medical history, that might
limit participation in or completion of the study. Volunteers
with a history of drug abuse, including alcohol, were
excluded. Volunteers were excluded if they were pregnant,
lactating or planning pregnancy, had severe allergy or a
history of a severe abnormal drug reaction. Other exclusion
criteria included: participation in a clinical trial (e.g. for an
experimental drug) within 4 weeks before the study, former
participation in a prebiotic or laxative trial within the
previous 3 months, use of antibiotics within the previous 6
months, chronic constipation, diarrhoea or other chronic
gastrointestinal complaints, and intake of other specific
prebiotics or probiotics, drugs active on gastrointestinal
motility, or a laxative of any class, for 4 weeks before the
study.
Requirements for diet and medication during the study.
The following were not permitted: intake of additional
prebiotics (such as oligosaccharides, e.g. FOS or inulin),
probiotics, live yoghurts, drugs active on gastrointestinal
motility, antibiotic treatment or any class of laxative. Any
medication taken was recorded in diaries. Volunteers were
instructed not to alter their usual diet or fluid intake during
the trial period.
Bacterial enumeration
Faecal samples were collected in sterile plastic pots and
stored at 48C, and processed within 2 h of collection. Freshly
voided faecal samples were diluted 1:10 (w/w) with
phosphate buffer (0:1 M; pH 7:0) and mixed in a stomacher
for 2 min. Changes in faecal bacterial populations were
assessed through the use of FISH with molecular probes
targeting 16S rRNA. Genotypic probes targeting predomi-
nant components of the gut microflora (bacteroides,
bifidobacteria, clostridia and lactobacilli) were manufac-
tured and tagged with fluorescent markers so that
quantifiable changes in faecal bacterial populations were
determined. The probes used were Bif164 (Langendijk et al.
1995), Bac303 (Manz et al. 1996), His150 (Franks et al.
1998) and Lab158 50GGTATTAGCA(T/C)CTGTTTCCA
(Harmsen et al. 1999), specific for bifidobacteria,
bacteroides, clostridia (Clostridium perfringens/histolyti-
cum sub.grp.) and Lactobacillus–Enterococcus spp.
respectively. The nucleic acid stain 406-diamidino-2-phe-
nylindole was used for total bacterial counts. Faecal samples
were diluted and fixed overnight in paraformaldehyde.
These cells were then washed with phosphate-buffered
saline (0:1 M-NaCl; pH 7:0), resuspended and stored at
2208C. The cell suspension was then added to the
hybridization mixture. Hybridization was carried out at
appropriate temperatures for the probes. Subsequently, the
hybridization mix was vacuum filtered and the filter was
mounted onto a microscope slide and examined under a
fluorescent microscope. The significance of changes in
bacterial numbers measured on ingestion of experimental
biscuits compared with bacterial numbers at pretreatment,
after ingestion of placebo biscuits, 7 and 14 d after cessation
of the intake of experimental biscuits and return to
pretreatment population levels, were assessed using the
matched paired t test.
Results
Bacteriology
Bacterial populations present in the thirty-one volunteers
over the experimental period are shown in Table 1. Bacterial
counts were determined using FISH and are expressed as
log10 cells/g faeces. No significant difference was observed
in the numbers of total bacteria, Bacteroides spp.,
Clostridium spp. or Lactobacillus spp. on ingestion of
either experimental or placebo biscuits. However, con-
sumption of experimental biscuits resulted in an increase in
bifidobacterial numbers of 0:487 log10 cells/g faeces from
pretreatment levels. A significant increase in Bifidobacter-
ium spp. was observed on ingestion of experimental biscuits
compared with ingestion of the placebo biscuits P 
2:15  1025: Bifidobacterial numbers increased from
pretreatment levels of 9:10 log10 cells/g faeces and placebo
levels of 9:18 log10 cells/g faeces, to 9:59 log10 cells/g
faeces after ingestion of the experimental biscuits.
In the sixteen volunteers who ingested experimental
biscuits during the second treatment, no significant
difference was observed between bifidobacterial numbers
7 d after cessation of treatment or from pretreatment
population levels (Table 2). A bifidobacterial population
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level of 9:55 log10 cells/g faeces after experimental
treatment decreased to 9:08 log10 cells/g on day 7 after
the end of intake of experimental biscuits. Clearly,
bifidobacterial population levels returned to approximately
pretreatment levels once volunteers stopped eating the
experimental biscuits (or at least within 7 d after
experimental treatment ceased).
Not all the volunteers responded in a similar manner to
ingestion of the experimental biscuits. Fig. 1 correlates the
change in bifidobacterial population levels observed in
faecal samples with the initial numbers for the thirty-one
volunteers. Those volunteers showing the lowest initial
bifidobacterial population levels gave the largest increase on
ingestion of the experimental biscuits. Fifteen of the
volunteers gave increases in bifidobacterial number of $ 0:5
log10 cells/g faeces, twelve gave increases of ,0:5 log10
cells/g faeces and in four volunteers bifidobacteria number
decreased after ingestion of the experimental biscuits
(Fig. 1). In volunteers showing initial bifidobacterial levels
of $ 9:45 log10 cells/g faeces, no major change in number
was observed after ingestion of the experimental biscuits.
Overall, bifidobacteria increased in number by more than
0:2 log10 cells/g faeces in 70 % of the volunteers. Little or no
change in numbers of total bacteria, Bacteroides spp.,
Clostridium spp. or Lactobacillus–Enterococcus spp. was
observed when data from this group were analysed
separately.
Gastrointestinal symptoms and digestive tolerance
Faecal pH changed little during the trial period. Mean faecal
pH for the thirty-one volunteers was 6:96, 7:08 and 7:05 for
pretreatment, placebo treatment and experimental treatment
faecal samples respectively. Similarly, no significant
difference was observed in mean daily stool frequency,
which was 1:61 (SD 0:94; n 31) during placebo treatment and
1:59 (SD 0:67; n 31) during experimental treatment. Some
volunteers did report increased occurrence of soft stools
during the first few days of intake of experimental biscuits.
Table 3 summarizes data on digestive tolerance
(flatulence, abdominal pain, bloating) and stool consist-
ency recorded by volunteers during biscuit intake. Stool
consistency, qualitatively graded by volunteers as
constipation, hard, formed, soft or diarrhoea, varied greatly
between individuals. The percentage coverage of each
category over the total number of responses given per
volunteer was determined. Ingestion of the placebo biscuits
gave a small increase in the percentage of stools described
as formed–constipation. Stools during experimental biscuit
intake were more often described as formed–soft. This
description was especially true of stool samples collected
during the first few days of ingestion of experimental
biscuits. The occurrence of abdominal pain, intestinal
bloating and flatulence were also qualitatively recorded
daily by volunteers in diaries under the categories none,
Table 2. Bifidobacterium spp. population levels (log10 cells/g faeces) determined by fluor-
escent in situ hybridization in sixteen volunteers given experimental biscuits containing par-
tially hydrolysed guar gum and fructo-oligosaccharides during the second treatment (T2)
stage*
(Mean values and standard deviations)
Pretreatment
Experimental
treatment (T2) T2 1 7 d T2 1 14 d
Return to
pretreatment
Mean SD Mean SD Mean SD Mean SD Mean SD
8:98a 0:49 9:55b 0:25 9:08a 0:45 8:83a 0:72 8:91† 0:50
a,bMean values with unlike superscript letters were significantly different (paired t test; P  4:99  1027).
* For details of subjects and procedures, see p. 342.
† Mean value was not significantly different from pretreatment value.
Table 1. Faecal bacterial numbers (log10 cells/g faeces) determined by fluorescent in situ hybridization
for thirty-one volunteers over the trial period during which they were given placebo biscuits or experi-
mental biscuits containing partially hydrolysed guar gum and fructo-oligosaccharides†
(Mean values and standard deviations)
Treatment group‡… Pretreatment Placebo Experimental Post-treatment
Bacterial group Mean SD Mean SD Mean SD Mean SD
Total bacteria 10:60 0:22 10:61 0:21 10:68 0:22 10:62§ 0:44
Bacteroides spp. 9:76 0:24 9:67 0:30 9:71 0:32 9:71§ 0:36
Bifidobacterium spp. 9:10 0:42 9:18 0:51 9:59* 0:26 8:98§ 0:41
Clostridium spp. 7:93 0:89 7:81 0:79 7:76 0:73 7:68§ 0:51
Lactobacillus spp. 7:71 0:44 7:71 0:38 7:72 0:55 7:62§ 0:43
Mean value was significantly different from that for the placebo group (paired t test): * P  2:15  1025:
† For details of subjects and procedures, see p. 342.
‡ Stool samples were collected at time points between days 214 and 0 (pretreatment), days 0 and 19–23 (placebo),
days 19–23 and 40–44 (experimental) and days 61–65 (post-treatment).
§ Mean values were not significantly different from those for the pretreatment group.
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mild, moderate and severe. The percentage coverage of
each category over the total number of responses given by
each volunteer was determined (Table 3). As with stool
consistency, the range and frequency of responses given by
different volunteers varied greatly. During experimental
treatment, a small increase in mild (6:09 %) and moderate
(7:28 %) abdominal pain was reported. There was also a
general trend towards a reporting of flatulence and
intestinal bloating as moderate during consumption of
experimental biscuits compared with mild during placebo
ingestion. Only two volunteers reported any severe or
significant increase in flatulence (and intestinal bloating in
one of these volunteers) during ingestion of experimental
biscuits.
Moderate and severe intestinal bloating increased by 5:09
and 18:38 % respectively, during experimental treatment
compared with placebo treatment. Moderate and severe
flatulence increased by 10:84 and 8:96 % respectively
during ingestion of the experimental biscuit.
Discussion
In the present study the prebiotic potential of PHGG and
FOS incorporated into a biscuit was assessed in thirty-one
healthy volunteers. The present study was carried out in a
double-blind randomized crossover manner, with volunteers
consuming experimental biscuits for 21 d and placebo
biscuits for 21 d. Bifidobacterium spp., Bacteroides spp.,
Clostridium spp. and Lactobacillus–Enterococcus spp.
were enumerated using FISH, and total bacteria were
determined using the fluorescent stain 40,6-diamidino-
2-phenylindole.
The prebiotic nature of FOS has been demonstrated
previously in various human volunteer studies (Gibson et al.
1995; Roberfroid et al. 1998), and PHGG has also been
shown to have a positive effect on gut motility (Homann
et al. 1994; Takahashi et al. 1994). However, there is little
information on the ability of specific prebiotics to retain
their functionality in final food products. Similarly, previous
studies have relied on traditional microbiological culture
techniques to monitor changes in gut microflora in response
to prebiotics. In view of recent observations relating to the
lack of specificity shown by so-called ‘selective agars’, and
the proportion of bacteria in the gut microflora that remain
unculturable, direct enumeration of micro-organisms in
environmental samples by the use of novel molecular
procedures constitutes a significant technological advance
(Ward et al. 1992; Amann et al. 1995; Nelson & George,
1995).
Fig. 1. Increase in bifidobacterial numbers in stool samples collected from thirty-
one volunteers as a function of initial pretreatment bifidobacterial population levels.
Bacterial counts are expressed as log10 cells/g faeces (mean of two samples) and
were determined using fluorescent in situ hybridization. The line of best fit through
the data (R 2 0:6465) shows that volunteers with the lowest initial levels of bifido-
bacteria gave the largest increase in bifidobacterial numbers on ingestion of the
experimental biscuits containing partially hydrolysed guar gum and fructo-oligosac-
charides.
Table 3. Summary of data recorded* in diaries by thirty-one volun-
teers over the course of the trial of intake of placebo biscuits or
experimental biscuits containing partially hydrolysed guar gum and
fructo-oligosaccharides†
(Mean values and standard deviations)
Treatment group… Placebo Experimental
Mean SD Mean SD
Stool consistency
Constipation 30:95 10:11 14:46 11:88
Hard 17:87 9:94 12:03 8:75
Formed 70:78 28:43 63:15 23:98
Soft 31:40 29:41 31:05 24:71
Diarrhoea 8:33 5:59 7:66 3:79
Digestive tolerance
Abdominal pain
None 89:04 15:76 77:16 23:64
Mild 15:34 11:58 21:43 18:87
Moderate 10:57 7:51 17:85 22:62
Severe 5:3 13:6
Intestinal bloating
None 80:95 25:44 64:21 30:91
Mild 32:70 28:25 32:30 21:30
Moderate 15:38 12:63 20:47 19:58
Severe – – 18:38 24:00
Flatulence
None 60:11 29:51 42:92 33:48
Mild 51:35 27:91 43:30 22:96
Moderate 18:38 12:01 29:22 15:78
Severe 6:75 2:76 15:71 20:53
* Percentage coverage of each category over the total number of responses
given per volunteer was determined.
† For details of subjects and procedures, see p. 342.
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In the present study consumption of biscuits containing
FOS and PHGG gave a significant increase in faecal
bifidobacterial numbers P  2:15  1025: Bifidobacteria
increased from 9:18 log10 cells/g faeces after the placebo
treatment to 9:59 log10 cells/g faeces after the experimental
treatment. Little or no change in the numbers of total
bacteria, Bacteroides spp., Clostridium spp. or Lacto-
bacillus–Enterococcus spp. present in faecal samples
collected over the course of the trial was observed. No
major changes in bacterial populations were observed on
ingestion of the placebo biscuits. In volunteers fed the
experimental biscuits during the second treatment period, no
significant difference was observed between bifidobacterial
populations 7 d after the end of active treatment and those in
pretreatment samples. This finding indicates that the
bifidogenesis observed on ingestion of the experimental
biscuits did not persist once treatment had ceased. Similarly,
in previous prebiotic feeding studies (Roberfroid et al.
1998), increases in the number of faecal bifidobacteria in
volunteers fed prebiotics returned to prefeeding levels once
prebiotic ingestion had ceased. Such observations illustrate
the selective nature of prebiotic fermentation in the colon,
and add weight to the concept of beneficial modulation of
the gut microflora through dietary supplementation with
functional foods. No changes in stool frequency or faecal
pH were observed in the present study. The severity and
frequency of reported changes in gastrointestinal symptoms
varied greatly between volunteers. In general, ingestion of
the experimental biscuits resulted in stools more often
described as formed–soft and a reduction in the reported
incidence of hard stools and constipation. However, a small
increase in abdominal pain, intestinal bloating and
flatulence was reported by some volunteers on ingestion
of the experimental biscuits. No correlation between the
level of increase in faecal bifidobacteria and gastrointestinal
symptoms was discerned, however. Bifidobacteria do not
produce gas during carbohydrate fermentation and, in the
present study, little difference in numbers of clostridia
(prolific gas producers) was observed on ingestion of the
experimental biscuits. The relationship between numbers of
specific bacteria in the gut microflora and gas production is
not well understood (Levitt et al. 1995). It is possible that
consumption of FOS or PHGG may result in increased gas
production, and associated increases in abdominal symp-
toms, without a concomitant increase in the numbers of the
bacterial groups that were monitored in the present study.
The relationship between gas economy in the colon, the
bacterial species involved and their metabolic response to
dietary components, including prebiotics, remains to be
clarified.
As noted previously (Roberfroid et al. 1998), a
correlation may exist between initial Bifidobacterium spp.
population levels and the magnitude of the increase in
bifidobacterial numbers observed in the volunteers fed
prebiotics. In the present study volunteers showing no
response to the experimental biscuits all possessed
relatively large populations of bifidobacteria (. 9:3 log10
cells/g faeces) in pretreatment faecal samples (Fig. 1).
The bifidogenic nature of a final food product containing
FOS and PHGG has been demonstrated in the present study.
Previous studies in human volunteers have determined the
bifidogenic nature of FOS (Gibson et al. 1995; Roberfroid
et al. 1998). Gibson et al. (1995) showed that its
consumption reduced numbers of Clostridium spp. and
Bacteroides spp. as well as increasing numbers of
bifidobacteria in human volunteers. No such reductions in
numbers of Clostridium spp. or Bacteroides spp. were
observed in the present study. Here, we employed a
powerful molecular technique (FISH) to enumerate bacteria
directly in situ in faecal samples, whereas previous studies
have relied on traditional microbiological culture tech-
niques. Selective agars rely on differing growth character-
istics of different bacterial groups. However, it is becoming
clear that phylogenetically unrelated bacterial species often
share phenotypic traits, allowing them to grow on
purportedly ‘selective’ agars (Woese, 1987; Nelson &
George, 1995). FISH, on the other hand, allows the
enumeration of bacteria that are closely related at the
phylogenetic level. Thus, in order to elucidate the effects of
FOS on clostridia and bacteroides populations in the human
gut microflora, it may be necessary to use a number of
different molecular and microbiological culture-based
techniques.
Bifidobacteria have long been regarded among the
beneficial members of the human gut microflora. One aspect
is the improved health benefits associated with the
bifidobacteria-dominated gut microflora of breast-fed infants
(Campbell & Jones, 1996; Vanderhoof & Young, 1998).
High numbers of bifidobacteria are also seen as positive for
adult health. Bifidobacteria have been shown to inhibit the
growth of pathogenic bacteria, to modulate the immune
system, to produce digestive enzymes, to repress the
activities of rotaviruses and to restore the microbial integrity
of the gut microflora following antibiotic therapy or
antibiotic-associated diarrhoea (Bernet et al. 1993; Gibson
& Wang, 1994; Saavedra et al. 1994, Collins & Gibson, 1999;
McCracken & Gaskins, 1999). Application of prebiotic
ingredients to food products conducive to the modern way of
living (e.g. biscuits and cereals) has the potential to improve
the gastrointestinal health of the population as a whole.
However, it is on the health of specific groups of individuals
with lowered bifidobacterial numbers in their gut microflora
that prebiotic foods may have the greatest impact. These
groups may include the elderly, individuals undergoing
antibiotic therapy or those with antibiotic-associated
diarrhoea and individuals with persistent gastrointestinal
conditions, such as inflammatory bowel disease or gastro-
enteritis. In the present study we have shown that healthy
volunteers with lower initial bifidobacterial populations in
faecal samples displayed the largest increases on consump-
tion of prebiotic-containing biscuits. Similar observations
have been made previously with FOS and inulin (Roberfroid
et al. 1998). Thus, prebiotic biscuits containing PHGG and
FOS may prove efficacious for increasing bifidobacterial
numbers in the gut microflora of those individuals with
lowered colonic bifidobacterial numbers. However, well-
designed placebo-controlled and, at least, double-blind
clinical trials are required to determine any health benefits
associated with increased gut bifidobacterial numbers in
such groups as patients with inflammatory bowel disease and
hospitalized elderly patients at risk of nosocomially and
antibiotic-acquired diarrhoea.
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